AMEI's Current Trends in Diagnosis & Treatment

Register      Login

VOLUME 5 , ISSUE 1 ( January-June, 2021 ) > List of Articles


A Study of COVID-19 Vaccine (COVISHIELD) Pharmacovigilance in Primary Healthcare Workers in Punjab, India

Rahat Kumar, Jaswinder Singh, Narinder Singh, Vikram Bhandari

Keywords : Coronavirus, Covishield, Pharmacovigilance, SARS-CoV-2

Citation Information : Kumar R, Singh J, Singh N, Bhandari V. A Study of COVID-19 Vaccine (COVISHIELD) Pharmacovigilance in Primary Healthcare Workers in Punjab, India. Curr Trends Diagn Treat 2021; 5 (1):6-11.

DOI: 10.5005/jp-journals-10055-0111

License: CC BY-NC 4.0

Published Online: 00-06-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Aims and Objectives: Coronavirus disease-2019 (COVID-19) is caused by a novel RNA coronavirus that can cause lethal diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome. Symptom onset is from 3 to 5 days with mild- to high-grade fever, persistent cough, mild to severe dyspnea with fall in SpO2, anosmia, ageusia, and fatigue. The management of COVID-19 infection includes oxygen, antiviral drugs like lopinavir or ritonavir, remdesivir, oseltamivir, favipiravir, ventilatory support, antibiotics, etc. Unfortunately, 100% recovery rate is not seen, and many patients die due to complications, so the main emphasis is on vaccine administration for the induction of virus-neutralizing antibodies. This study was done to assess the safety of Covishield in primary healthcare workers so as to assess the risk assessment in general population. Materials and methods: Covishield (ChAdOx1 nCoV-19), a coronavirus vaccine (recombinant), is manufactured by the Serum Institute of India Pvt. Ltd. Pune, India. Covishield has been approved for emergency authorization against COVID-19 infection. Covishield during phase I vaccination drive after consent was given to the 1,054 healthcare workers of Sri Guru Ram Das Institute of Medical Sciences and Research (SGRDIMSAR), Amritsar, and safety data were generated in postvaccination phase. Results: It was observed that there were 97.3% of solicited reactions and 2.7% of unsolicited reactions. Most of the solicited reactions were pain at the injection site, mild fever, malaise, and headache with a duration of symptoms generally for 2–3 days. In the unsolicited reactions, mainly moderate- to high-grade fever followed by decreased appetite and dizziness with a duration of 2–3 days were observed. Only in one subject, an increase in liver function test occurred for 3 days. Conclusion: The findings of our study indicate that Covishield vaccine has provided excellent tolerability in health care subjects who willingly received the vaccine during phase I mass vaccination, and there was no report of any untoward side effects demanding attention in such patients. Clinical significance: The tolerability of Covishield vaccine observed in the present study can be used to extrapolate the safety in the general population. Thus, mass vaccination with Covishield is recommended in the general population without any fear of vaccine-related serious side effects.

PDF Share
  1. CDC. 2019 novel coronavirus. Wuhan, China: CDC; 2020. Available at: [Accessed: January 27, 2020].
  2. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. 2020. Available at: [Accessed: February 13, 2020].
  3. CDC. 2019 novel coronavirus, Wuhan, China: symptoms. CDC; 2020. Available at: [Accessed: January 27, 2020].
  4. WHO coronavirus disease (COVID-19) dashboard. World Health Organization; 2021. Available at: [Accessed: February 8, 2021].
  5. Kaplan EH. Containing 2019-nCoV (Wuhan) coronavirus. Health Care Manag Sci 2020;23:311–314. DOI: 10.1007/s10729-020-09504-6.
  6. India continues saving lives and livelihoods – recording more COVID-19 recoveries while lifting restrictions. Available at: [Accessed: February 18, 2021].
  7. World's largest vaccination programme begins in India on January 16. The Hindu. January 15, 2021 [Retrieved: January 16, 2021].
  8. Moore JP, Klasse PJ. SARS-CoV-2 vaccines: “Warp Speed” needs mind melds not warped minds. J Virol 2020;94(17):1–32. DOI: 10.1128/JVI.01083-20.
  9. Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7(3):226–236. DOI: 10.1038/nrmicro2090.
  10. Nath S. Updates on COVID-19 vaccine development and India's roles in vaccine preparation. Int J Sci Res 2020;9(8);137–140.
  11. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396(10249):467–478. DOI: 10.1016/S0140-6736(20)31604-4.
  12. Coronavirus disease (COVID-19): vaccines serum – protection from birth onwards. ChAdOx1 nCoV-19 corona virus vaccine (Recombinant) COVISHIELD™. Available at:
  13. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial. Lancet 2020;395(10240):1845–1854. DOI: 10.1016/S0140-6736(20)31208-3.
  14. Moderna announces positive interim phase 1 data for its mRNA vaccine (mRNA-1273) against novel coronavirus. May 18, 2020. Available at:, authorization by DCGI-CDSCO, MoH and FW on January 3, 2021.
  15. DCGI approves Covishield and Covaxin for restricted emergency use in India. DCGI's decision comes after the Subject Expert Committee of CDSCO met on January 1–2, 2021 and recommended the grant of permission for restricted emergency use of these vaccines. Available at:
  16. Indian vaccine market report and forecast 2020–2025. Available at:,
  17. Knolla MD, Wonodia C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet 2021;397(10269):72–74. DOI: 10.1016/S0140-6736(20)32623-4.
  18. Council for International Organizations of Medical Sciences (CIOMS). Definition and application of terms of vaccine pharmacovigilance (report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance). Genève: CIOMS; 2012.
  19. Fact sheet for vaccine recipient approved for restricted use in emergency situation of Chadox1 ncov-19 corona virus vaccine (recombinant). Available at:
  20. Voysey M, Costa Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Oxford COVID Vaccine Trial Group. Lancet 2021;397(10269):99–111. DOI: 10.1016/S0140-6736(20)32661-1.
  21. Tapia MD, Sow SO, Mbaye KD. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2020;20(6):719–730. DOI: 10.1016/S1473-3099(20)30019-0.
  22. Sah R, Shrestha S, Mehta R, et al. AZD1222 (Covishield) vaccination for COVID-19: experiences, challenges, and solutions in Nepal. Travel Med Infect Dis 2021;40:101989. DOI: 10.1016/j.tmaid.2021.101989.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.